Ramucirumab. Anti-VEGFR-2 human monoclonal antibody antiangiogenic

Drugs of the Future

Volumn 37, Issue 7, 2012, Pages 483-488

  Spratlin, Jennifer L ^a   Mulder, Karen E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anti VEGFR 2 antibody; Antiangiogenic agent; IMC 1121B; Ramucirumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DACARBAZINE; DOCETAXEL; GEMCITABINE; ICRUCUMAB; IMMUNOGLOBULIN G1; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PEMETREXED; PREDNISONE; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEINURIA; RECURRENT CANCER; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; STOMACH CANCER; TREATMENT OUTCOME; URETHRA CANCER; UTERUS SARCOMA; VOMITING;

EID: 84952976047     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2012.037.07.1854606     Document Type: Review

References (34)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1): 27-31.
2. Kerbel, R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000, 21(3): 505-15. (Pubitemid 30137936)
3. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801): 249-57.
4. Veikkola, T., Alitalo, K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999, 9(3): 211-20. (Pubitemid 29273837)
5. de Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255(5047): 989-91.
6. Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., Sato, M. Nucleotide sequence and expression of a novel human recep-tor- type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5(4): 519-24.
7. Klagsbrun, M., D'Amore, P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996, 7(3): 259-70. (Pubitemid 27200310)
8. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935): 1306-9. (Pubitemid 20066716)
9. Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P., Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1(2): 193-202. (Pubitemid 41039165)
10. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23): 2335-42. (Pubitemid 38702844)
11. Sandler, A., Gray, R., Perry, M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24): 2542-50. (Pubitemid 44917502)
12. Kreisl, T.N., Kim, L., Moore, K. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5): 740-5.
13. Friedman, H.S., Prados, M.D., Wen, P.Y. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28): 4733-40.
14. Rini, B.I., Halabi, S., Taylor, J., Small, E.J., Schilsky, R.L. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004, 10(8): 2584-6. (Pubitemid 38509129)
15. Demetri, G.D., van Oosterom, A.T., Garrett, C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368(9544): 1329-38. (Pubitemid 44528723)
16. Motzer, R.J., Hutson, T.E., Tomczak, P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(22): 3584-90.
17. Raymond, E., Dahan, L., Raoul, J.L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6): 501-13.
18. Llovet, J.M., Ricci, S., Mazzaferro, V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4): 378-90.
19. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20): 3312-8.
20. Ton, N.C., Parker, G.J., Jackson, A. et al. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 2007, 13(23): 7113-8. (Pubitemid 350276896)
21. Posey, J.A., Ng, T.C., Yang, B. et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003, 9(4): 1323- 32.
22. Lu, D., Jimenez, X., Zhang, H., Bohlen, P., Witte, L., Zhu, Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002, 97(3): 393-9. (Pubitemid 34049034)
23. Lu, D., Shen, J., Vil, M.D. et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003, 278(44): 43496-507. (Pubitemid 37345973)
24. Zhu, Z., Hattori, K., Zhang, H. et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003, 17(3): 604-11. (Pubitemid 36395655)
25. Prewett, M., Huber, J., Li, Y. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999, 59(20): 5209-18. (Pubitemid 29503984)
26. Bruns, C.J., Liu, W., Davis, D.W. et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000, 89(3): 488-99. (Pubitemid 30640095)
27. Spratlin, J.L., Cohen, R.B., Eadens, M. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28(5): 780-7.
28. Spratlin, J.L., Mulder, K.E., Mackey, J.R. Ramucirumab (IMC-1121B): A novel attack on angiogenesis. Future Oncol 2010, 6(7): 1085-94.
29. Zhu, A.X., Finn, R.S., Mulcahy, M. et al. A phase 2 study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC): Updated results (CP12-0710/NCT00627042). 2010 Int Liver Cancer Assoc (Sept 10-12, Montreal) 2010, Abst O-033.
30. Garcia, J., Hudes, G., Choueiri, T. et al. Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12-0605/NCT00515697). 2010 Genitourin Cancers Symp (March 5-7, San Francisco) 2010, Abst 326.
31. Motzer, R.J., Escudier, B., Oudard, S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637): 449-56.
32. Hudes, G., Carducci, M., Tomczak, P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22): 2271-81. (Pubitemid 46849157)
33. Camidge, D., Ballas, M., Dubey, S. et al. A phase 2, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody targeting VEGFR-2, in combination with paclitaxel and carboplatin as firstline therapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) (CP12-0708/NCT00735696). 47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011, Abst 7588.
34. Penson, R.T., Moore, K.N., Fleming, G.F. et al. A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). 48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012, Abst 5012.